首页> 外文期刊>Journal of clinical laboratory analysis. >Simultaneous determination of alpha-fetoprotein immune complexes and alpha-fetoprotein concentration in hepatocellular carcinoma using dual-label time-resolved immunofluorometric assays.
【24h】

Simultaneous determination of alpha-fetoprotein immune complexes and alpha-fetoprotein concentration in hepatocellular carcinoma using dual-label time-resolved immunofluorometric assays.

机译:使用双标记时间分辨免疫荧光测定法同时测定肝细胞癌中的甲胎蛋白免疫复合物和甲胎蛋白浓度。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Alpha-fetoprotein (AFP) is a commonly used tumor marker in the detection of hepatocellular carcinoma (HCC), and its sensitivity and specificity is insufficient to detect HCC in all patient samples. Recently, the immunocomplexed forms of AFP (AFP-IgM) have been reported to be present in HCC patients. This study was aimed at developing a novel time-resolved immunofluorometric assay (TR-IFMA) for the simultaneous determination of AFP-IgM and AFP concentration in HCC. We constructed a double-label assay by using Sm3+-labeled mAb to human IgM antibody, Eu3+-labeled mAb to AFP, and immobilized another mAb to AFP on the solid phase. The performances of the assay were all found to be satisfactory. The validity of the novel assay was confirmed by the good correlation between the results obtained by TR-IFMA and commercial ELISA or electrochemiluminescence immunoassay. AFP-IgM and AFP were increased above the cutoffs in 65.25 and 45.76% of HCC, respectively. ROC analysis yielded the following area under the curve: AFP-IgM 0.774 (CI 95% 0.736-0.809), AFP 0.771 (CI 95% 0.733-0.860). The combined use of AFP-IgM and AFP increased the sensitivity of detection to 72.88% in patients with HCC. These data suggest that the use of a combination of two markers in clinical practice could increase the accuracy of HCC diagnosis.
机译:甲胎蛋白(AFP)是肝细胞癌(HCC)检测中常用的肿瘤标志物,其敏感性和特异性不足以检测所有患者样品中的HCC。近来,据报道在肝癌患者中存在免疫复合形式的AFP(AFP-IgM)。这项研究旨在开发一种新型的时间分辨免疫荧光测定法(TR-IFMA),用于同时测定肝癌中的AFP-IgM和AFP浓度。我们通过使用针对人IgM抗体的Sm3 +标记的mAb,针对AFP的Eu3 +标记的mAb,构建了双标记测定法,并将另一mAb固定于AFP在固相上。发现该测定的性能均令人满意。 TR-IFMA与商业ELISA或电化学发光免疫测定法之间的良好相关性证实了该新型测定法的有效性。在肝癌中,AFP-IgM和AFP分别高于临界值65.25和45.76%。 ROC分析在曲线下产生以下面积:AFP-IgM 0.774(CI 95%0.736-0.809),AFP 0.771(CI 95%0.733-0.860)。 AFP-IgM和AFP的联合使用可将HCC患者的检测灵敏度提高到72.88%。这些数据表明,在临床实践中结合使用两种标记物可以提高HCC诊断的准确性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号